Edgewise Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €394.17M +182.3% €50.89M -135.8% 12.9% +1.1 pp N/A N/A
    (estimated) €139.64M +391.8% -€142.05M -29.9% -101.7% +6.1 pp N/A N/A
    (estimated) €28.39M +1,366.5% -€202.52M +10.3% -713.2% +88 pp -€204.66M +42.0% -720.8% +67 pp
    (estimated) €1.94M +∞% -€183.62M +30.4% -9,483.7% -95 pp -€144.15M +30.0% -7,444.9% -74 pp
    (estimated) €0.00 +NaN% -€140.86M +23.4% N/A -€110.88M +20.7% N/A
    €0.00 +NaN% -€114.14M +33.6% N/A -€91.88M +25.0% N/A
    €0.00 +NaN% -€85.43M +550.5% N/A -€73.53M +83.1% N/A
    €0.00 +NaN% -€13.13M -63.5% N/A -€40.16M +43.4% N/A
    €0.00 +NaN% -€35.94M +147.1% N/A -€28.01M +127.6% N/A
    €0.00 +NaN% -€14.55M +79.8% N/A -€12.31M +60.5% N/A
    €0.00 -€8.09M N/A -€7.67M N/A

    Notifications